MARKET

ALGS

ALGS

Aligos Therapeutics, Inc.
NASDAQ
9.16
+0.12
+1.33%
After Hours: 8.83 -0.33 -3.60% 19:26 07/18 EDT
OPEN
9.19
PREV CLOSE
9.04
HIGH
9.48
LOW
8.84
VOLUME
79.67K
TURNOVER
--
52 WEEK HIGH
46.80
52 WEEK LOW
3.760
MARKET CAP
56.01M
P/E (TTM)
-0.8814
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALGS last week (0707-0711)?
Weekly Report · 6d ago
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
TipRanks · 07/11 12:35
ALIGOS THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 07/11 12:30
Weekly Report: what happened at ALGS last week (0630-0704)?
Weekly Report · 07/07 09:16
Weekly Report: what happened at ALGS last week (0623-0627)?
Weekly Report · 06/30 09:17
Aligos Therapeutics Approves Major Amendments at Annual Meeting
TipRanks · 06/26 20:30
Weekly Report: what happened at ALGS last week (0616-0620)?
Weekly Report · 06/23 09:16
Aligos Therapeutics appoints Kieron Wesson as VP, head of CMC
TipRanks · 06/18 12:05
More
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Webull offers Aligos Therapeutics Inc stock information, including NASDAQ: ALGS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALGS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALGS stock methods without spending real money on the virtual paper trading platform.